

Regular Meeting of the

## Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, December 16, 2021, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

# Minutes (Open) - Approved

---

### Members Present

Jimmy Lin, MD, Chair  
Ali Alkoraishi, MD  
Xuan Cung, PharmD  
Dang Huynh, PharmD, Director of Pharmacy and UM  
Laurie Nakahira, DO, Chief Medical Officer  
Judy Ngo, PharmD  
Peter Nguyen, DO  
Jesse Parashar-Rokicki, MD

### Members Absent

Dolly Goel, MD

### Staff Present

Kathy Le, PharmD, Pharmacy Resident  
Duyen Nguyen, PharmD, Clinical Pharmacist  
Tami Otomo, PharmD, Clinical Pharmacist  
Nancy Aguirre, Administrative Assistant

### Others Present

Amy McCarty, PharmD, MedImpact

## 1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:06 pm. Roll call was taken and a quorum was established.

## 2. Public Comment

There were no public comments.

## 3. Open Meeting Minutes

The 3Q2021 P&T Committee open meeting minutes were reviewed.

**It was moved, seconded and** the open minutes of the 3Q2021 P&T meeting minutes were **unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Lin

**Ayes:** Dr. Alkoraishi, Dr. Cung, Dr. Huynh, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

#### 4. Standing Agenda Items

##### a. Chief Medical Officer Health Plan Updates

Laurie Nakahira, DO, Chief Medical Officer (CMO), presented the CMO Health Plan Updates. Dr. Nakahira reported the current Plan membership is approximately 286,552 members, reflecting a 9.1% increase over the last year, September 2020. This increase is largely attributable to a hold on disenrollment of Medi-Cal members. When the Department of Health Care Services (DHCS) reactivates disenrollment, there will likely be a decrease in membership.

Dr. Nakahira announced the National Committee for Quality Assurance (NCQA) Cal MediConnect (CMC) Resurvey is coming up on January 31, 2022 to February 2, 2022. In addition, CalAIM, Enhanced Care Management (ECM), and In Lieu of Services (ILOS) will begin on January 1, 2022.

Currently, the Plan has placed a hold on returning to office due to concerns about the COVID-19 delta variant. All committee meetings will continue to be held via teleconference.

DHCS has initiated a COVID incentive program to address vaccine disparities. Out of SCFHP's Medi-Cal (MC) membership, approximately 56.9% are fully vaccinated and 5.7% are partially vaccinated. Out of SCFHP's CMC membership, approximately 75.8% are fully vaccinated and 4.5% are partially vaccinated. SCFHP will be participating in this incentive program to aid in closing gaps by offering MC members and providers incentives, partnering with community leaders, and conducting outreach to vulnerable populations. SCFHP will also be hosting COVID vaccine administration events at the Community Resource Center (CRC).

Dr. Nakahira noted that the CRC will be doing an opening kick-off on October 2, 2021.

***Judy Ngo joined the meeting at 6:12p.m.***

##### b. Grievance & Appeals 2Q 2021 and 3Q 2021 Pharmacy Reports

Mauro Oliveira, Manager, Grievance and Appeals, presented the Grievance & Appeals (G&A) 2Q 2021 and 3Q 2021 Pharmacy records.

##### c. Medi-Cal Rx Update

Tami Otomo, PharmD, Clinical Pharmacist, noted the Medi-Cal Rx Carve Out will be implemented on January 1, 2022. Starting on this date, the pharmacy benefit for MC members will be carved back into the state. SCFHP will be identifying members who may require more assistance during this transition and work with pharmacy partners to ease the transition. DHCS will send a 60-day notice to members, and the Plan will send a 30-day notice to members. The Plan is also working on updating member and provider material and will be conducting additional provider communication. Provider training and portal enrollment is available on the Medi-Cal Rx website.

##### d. Policy Review – PH.12 Drug Management Program

Dang Huynh, PharmD, Director, Pharmacy and Utilization Management, presented the updates to the PH.12 Drug Management Program.

##### e. Plan/Global Medi-Cal Drug Use Review

###### i. Drug Utilization Evaluation Update

Dr. Otomo shared the results from SCFHP's quarterly retrospective Drug Use Evaluation (DUE) program. For Q3 2021, the focus was Asthma for both lines of business. This program identified members receiving four or more prescriptions for an asthma medication over a 12-month period and are not on a controller medication. For MC, there were 662 impacted members, and 324 providers were mailed letters on August 18, 2021. For CMC, there were 88 impacted members, and 68 providers were emailed letters on August 18, 2021.

**f. Emergency Supply Report – 3Q 2020, 4Q 2020**

Duyen Nguyen, PharmD, Clinical Pharmacist, reviewed the Emergency Supply Report for Q3 and Q4, 2020. Dr. Nguyen reported in Q3 2020, SCFHP had a total of 15,834 ER visits from claims and encounter data. Approved claims were appropriate. There were no inappropriate denied claims. For no claims, there were no issues with the completed charts that were reviewed.

***Adjourned to Closed Session at 6:21p.m.  
Pursuant to Welfare and Institutions Code Section 14087.36 (w)***

**5. Closed Meeting Minutes**

The 3Q2021 P&T Committee closed meeting minutes were reviewed.

**It was moved, seconded and the closed minutes of the 3Q2021 P&T meeting minutes were unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Alkoraishi

**Ayes:** Dr. Cung, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

**6. Metrics and Financial Updates**

**a. Membership Report**

The Membership Report was presented by Dr. Nakahira during the CMO Update.

**b. Pharmacy Dashboard**

Dr. Otomo reviewed the Pharmacy Dashboard.

**c. Drug Utilization & Spend – 3Q 2021**

Amy McCarty, PharmD, MedImpact, presented the Drug Utilization and Spend for 3Q 2021.

**7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria**

**a. Pharmacy Benefit Manager 3Q 2021 P&T Minutes**

Dr. McCarty referenced the Pharmacy Benefit Manager 3Q 2021 P&T Minutes included in the meeting packet.

**b. Pharmacy Benefit Manager 4Q 2021 P&T Part D Actions**

Dr. McCarty reviewed the Pharmacy Benefit Manager 4Q 2021 P&T Part D Actions.

**It was moved, seconded and the MedImpact Minutes and Actions were unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Lin

**Ayes:** Dr. Alkoraishi, Dr. Cung, Dr. Huynh, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

**c. 2022 Medical Benefit Drug Prior Authorization Grid**

Dr. Otomo reviewed the 2022 Medical Benefit Drug PA Grid for CMC.

**It was moved, seconded and the 2022 Medical Benefit Drug PA Grid was unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Lin

**Ayes:** Dr. Alkoraishi, Dr. Cung, Dr. Huynh, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

## 8. Discussion and Recommendations for Changes to SCFHP's Medi-Cal Formulary & Prior Authorization Criteria

### a. Old Business/Follow-Up

- i. PCSK9 Inhibitors
- ii. Trijardy XR

### b. Formulary Modifications

Dr. Otomo presented the changes made to the Medi-Cal formulary since the last P&T Committee meeting.

**It was moved, seconded and the Formulary Modification were unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Alkoraishi

**Ayes:** Dr. Cung, Dr. Huynh, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

### c. Fee-for-Service Contract Drug List Comparability

Dr. McCarty reviewed the Fee-for-Service (FFS) Contract Drug List (CDL) Comparability for MC.

**It was moved, seconded and the FFS Contract Drug List Comparability was unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Alkoraishi

**Ayes:** Dr. Cung, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

### d. 2022 Medical Benefit Drug Prior Authorization Grid

Dr. Otomo reviewed the 2022 Medical Benefit Drug PA Grid for Medi-Cal.

**It was moved, seconded and the 2022 Medical Benefit Drug PA Grid was unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Alkoraishi

**Ayes:** Dr. Cung, Huynh, Dr. Lin, Dr. Nakahira Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

### e. Prior Authorization Criteria

Dr. Nguyen reviewed the PA Criteria.

#### g. New or Revised Criteria

1. Stromectol – *new criteria*
2. Zeposia – *new criteria*

#### h. Annual Review

1. Non-formulary – *no changes*
2. Norditropin Flexpro – *no changes*
3. Protopic Ointment – *no changes*
4. Zarxio – *no changes*

**It was moved, seconded and the PA Criteria Recommendations were unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Cung

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Goel

## 9. New Drugs and Class Reviews

### a. COVID-19 Updates

Dr. McCarty reviewed the COVID-19 updates.

**b. Inhaled tobramycin**

Dr. McCarty reviewed Inhaled Tobramycin.

**c. Difucid**

Dr. McCarty reviewed Difucid.

**d. New and Expanded Indications – Nucala, Facenra, Xywav**

Dr. McCarty reviewed Nucala, Facenra, and Xywav.

**e. New Entities, Derivatives & Formulations – Tyrvaya, Myrbetriq granules, Trudhesa**

Dr. McCarty reviewed Tyrvaya, Myrbetriq granules, and Trudhesa.

**f. Informational only:**

- i. **Myelofibrosis – pacritinib**
- ii. **Presbyopia – Presbysol**
- iii. **Acute agitation – dexmedetomidine**
- iv. **Pulmonary hypertension**
- v. **Weight loss agents**
- vi. **Continuous glucose monitors**
- vii. **Drugs: Pennsaid, Santyl, Kuvan, Upneeq, Cosentyx, omidenepag, isopropyl, maribavir, daridorexant, tezepelumad**

**It was moved, seconded and the recommendations for New Drugs and Class Reviews were unanimously approved.**

**Motion:** Dr. Nguyen

**Second:** Dr. Cung

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Parashar-Rokicki, Dr. Ngo

**Absent:** Dr. Goel

***Reconvene in Open Session at 7:58 p.m.***

**10. Discussion Items**

**a. New and Generic Pipeline**

Dr. McCarty reviewed the New and Generic Pipeline. There were no notable new or generic drugs, aside from Revlimid Vimpat, expected for release in March, 2022.

**11. Adjournment**

The meeting adjourned at 8:00p.m. The next P&T Committee meeting will be on Thursday, March 17, 2022.

---

Jimmy Lin, MD, Chair

---

Date